Call for Abstracts for DPL XXXVII Is Now Open!
ASPL is a non-profit which encourages diversity & inclusion with the Society, regardless of differing backgrounds, perspectives, experiences, orientations, origins, and practice settings. The Society embraces participation and diversity as it leads to advancing our purpose:
Latest NewsFDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s FDA issued 30 warning letters to telehealth companies for making false and misleading claims regarding compounded GLP-1 products offered on their websites. This is the second group of warning letters sent to telehealth firms since the agency launched in September a crackdown on misleading direct-to-consumer pharmaceutical advertisements. Over the past six months, the agency has sent thousands of letters warning pharmaceutical and telehealth firms to remove misleading ads, more than had been sent over the entire preceding decade. Primary violations identified in the letters included making claims implying sameness with FDA-approved products and obscuring product sourcing by advertising drug products branded with the telehealth firm’s name or trademark without qualification, implying they are the compounder. [FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. FDA 03 Mar 2026.]
|